title: Intractable epilepsies. An open trial with Clobazam.
abstract: Clobazam was used as an added treatment in 28 patients with intractable epilepsies: 26 subjects had associated handicaps. A good response was observed during the first two-three months of Clobazam treatment: the reduction in seizure frequency of 73% for partial seizures and 62% for GTCs. A tolerance to Clobazam treatment was observed after the third month of treatment: at the end of the sixth month, the seizure frequency was reduced to 36% for partial seizures and 39% for GTCs. Out of 28 patients 4 were seizure free at the end of the sixth month; we have not found any specific characteristic in these patients. The AA. suggest the possibility of an intermittent use of Clobazam for this type of patients.
authors.forename: C M
authors.initials: CM
authors.lastname: Cornaggia
authors.forename: G
authors.initials: G
authors.lastname: Cattabeni
authors.forename: N
authors.initials: N
authors.lastname: Cerisola
authors.forename: C
authors.initials: C
authors.lastname: Leozappa
authors.forename: P L
authors.initials: PL
authors.lastname: Mascetti
authors.forename: R
authors.initials: R
authors.lastname: Massironi
authors.forename: G
authors.initials: G
authors.lastname: Porro
authors.forename: E
authors.initials: E
authors.lastname: Manghi
mesh_terms: D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000078306:Clobazam; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; D000078306:Clobazam